Analysts Expect TherapeuticsMD Inc (TXMD) Will Announce Earnings of -$0.10 Per Share

Wall Street analysts predict that TherapeuticsMD Inc (NASDAQ:TXMD) will post earnings per share of ($0.10) for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for TherapeuticsMD’s earnings. The highest EPS estimate is ($0.08) and the lowest is ($0.11). TherapeuticsMD posted earnings of ($0.11) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 9.1%. The firm is expected to announce its next quarterly earnings report on Tuesday, May 1st.

On average, analysts expect that TherapeuticsMD will report full year earnings of ($0.40) per share for the current financial year, with EPS estimates ranging from ($0.69) to $0.18. For the next fiscal year, analysts expect that the business will report earnings of ($0.06) per share, with EPS estimates ranging from ($0.35) to $0.24. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that cover TherapeuticsMD.

How to Become a New Pot Stock Millionaire

TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings results on Tuesday, February 20th. The company reported ($0.10) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.01). The company had revenue of $4.13 million during the quarter, compared to analysts’ expectations of $4.66 million. TherapeuticsMD had a negative net margin of 458.49% and a negative return on equity of 63.67%. TherapeuticsMD’s revenue for the quarter was down 8.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.12) earnings per share.

Several brokerages have recently weighed in on TXMD. Cantor Fitzgerald reiterated a “buy” rating and issued a $28.00 price target on shares of TherapeuticsMD in a research report on Sunday, January 7th. Oppenheimer reiterated a “buy” rating and issued a $10.00 price target on shares of TherapeuticsMD in a research report on Sunday, January 28th. Zacks Investment Research upgraded TherapeuticsMD from a “sell” rating to a “hold” rating in a research report on Saturday, January 20th. BidaskClub upgraded TherapeuticsMD from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 3rd. Finally, Deutsche Bank set a $9.00 price target on TherapeuticsMD and gave the company a “buy” rating in a research report on Wednesday, December 20th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $14.50.

Institutional investors have recently bought and sold shares of the stock. MANA Advisors LLC purchased a new position in TherapeuticsMD during the fourth quarter worth about $104,000. Paloma Partners Management Co purchased a new position in TherapeuticsMD during the fourth quarter worth about $105,000. Edge Wealth Management LLC grew its position in TherapeuticsMD by 2,500.0% during the fourth quarter. Edge Wealth Management LLC now owns 20,800 shares of the company’s stock worth $125,000 after buying an additional 20,000 shares in the last quarter. Claraphi Advisory Network LLC purchased a new position in TherapeuticsMD during the fourth quarter worth about $275,000. Finally, Teacher Retirement System of Texas grew its position in TherapeuticsMD by 332.0% during the fourth quarter. Teacher Retirement System of Texas now owns 58,000 shares of the company’s stock worth $350,000 after buying an additional 44,574 shares in the last quarter. Institutional investors and hedge funds own 73.31% of the company’s stock.

Shares of NASDAQ TXMD traded up $0.01 during mid-day trading on Friday, hitting $5.83. The company had a trading volume of 1,213,257 shares, compared to its average volume of 1,937,715. The stock has a market cap of $1,237.81, a PE ratio of -15.92 and a beta of 1.36. TherapeuticsMD has a 1 year low of $3.50 and a 1 year high of $7.01.

COPYRIGHT VIOLATION WARNING: This report was first reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at https://www.thelincolnianonline.com/2018/04/19/analysts-expect-therapeuticsmd-inc-txmd-will-announce-earnings-of-0-10-per-share.html.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc is a healthcare company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.

Get a free copy of the Zacks research report on TherapeuticsMD (TXMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply